SMMT · Summit Therapeutics Inc.
$14.50
-6.27% last session
End-of-day data · close of 2026-10-26
Market cap
$12B
Enterprise value
$11B
Trailing P/E
—
Forward P/E
-16.5
Dividend yield
0.0%
Beta
-1.52
Avg volume
6M
Employees
0K
Daily Change %
-6.27%
5 Days Change
-6.75%
10 Days Change
-0.89%
30 Days Change
-7.11%
60 Days Change
5.61%
Month to Day Change
-13.12%
Year to Day Change
-17.10%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — SMMT
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-01
Latest call per bank · past 12 months
Barclays
Equal-Weight$20.00
+37.9% vs priceCitigroup
Buy$43.00
+196.6% vs priceJefferies
Buy$25.00
+72.4% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-01 | Barclays | Maintains | Equal-Weight | $18.00 → $20.00 |
| 2026-09-29 | Citigroup | Maintains | Buy | $40.00 → $43.00 |
| 2026-09-23 | HC Wainwright & Co. | Reiterates | Neutral | $0.00 |
| 2026-09-09 | Jefferies | Upgrade | Hold → Buy | $15.00 → $25.00 |
| 2026-08-26 | HC Wainwright & Co. | Reiterates | Neutral | $0.00 |
| 2026-08-25 | Bernstein | Upgrade | Underperform → Market Perform | $9.80 → $11.90 |
| 2026-08-18 | HC Wainwright & Co. | Reiterates | Neutral | $0.00 |
| 2026-08-12 | Leerink Partners | Upgrade | Underperform → Market Perform | $12.00 → $13.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-26
- neutral: RSI (14): RSI is 39 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 8.3% below the 50-day MA ($15.81).
- bearish: Price vs 200-day MA: Trading 10.6% below the 200-day MA ($16.22).
- bearish: MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- bearish: MACD (12,26,9): MACD histogram is negative (-0.20) — short-term momentum is fading.
- neutral: 52-week range: Price sits between the 52-week low ($12.43) and high ($26.38).
SMMT Price Chart
Loading chart for SMMT…
Fundamentals
About Summit Therapeutics Inc.
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$131B 14.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 5.0% YTD
MRNA
Moderna, Inc.
$79B 574.3% YTD
ARGX
argenx SE
$55B 3.4% YTD
ONC
BeOne Medicines Ltd.
$42B 22.1% YTD
RVMD
Revolution Medicines, Inc.
$39B 130.9% YTD
RPRX
Royalty Pharma plc
$37B 69.9% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.